MRK logo Merck & Co. +
Merck & Co.
+

Merck & Co. (MRK) Business News

Track Merck & Co. in real time with a live news feed covering Merck & Co. stock news, official press releases, company announcements, and an archive of historical Merck & Co. news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection

Merck Inks $2.1B Deal With Chinese Biotech to Expand Oncology Pipeline

Zacks Investment Research

12:16 PM | Tuesday | Sep 29, 2026

news photo
Loading...

MRK's $2.13 billion deal for SPR2015 adds a preclinical KRAS G12D inhibitor to its precision oncology pipeline, targeting a common cancer mutation.

Read full article redirect
12:16 PM | Tuesday | Sep 29, 2026

Merck Inks $2.1B Deal With Chinese Biotech to Expand Oncology Pipeline

Zacks Investment Research

MRK's $2.13 billion deal for SPR2015 adds a preclinical KRAS G12D inhibitor to its precision oncology pipeline, targeting a common cancer mutation.

Read full article arrow
News Thumbnail
11:27 AM | Tuesday | Sep 29, 2026

Merck Turned $1,000 Into $3,395 in a Decade but the Real Story Happened in the Last Year

24/7 Wall Street

Merck spent most of a decade trailing the S&P 500, then something unusual happened in a single year that changed the entire math.

Read full article arrow
News Thumbnail
9:56 AM | Tuesday | Sep 29, 2026

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Zacks Investment Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Read full article arrow
News Thumbnail
10:39 AM | Monday | Sep 28, 2026

US drugmakers turn to China for licensing deals

Reuters

Merck on Monday agreed to pay Chinese biotech SciBrunch Therapeutics $400 million upfront for global ​rights to an experimental cancer drug, making ‌it the latest US drugmaker to license China-developed medicines.

Read full article arrow
News Thumbnail
7:41 AM | Monday | Sep 28, 2026

Merck licenses SciBrunch cancer drug in deal worth up to $2.13 billion

Reuters

Merck said on Monday it would pay up to $2.13 billion under a ​global licensing deal with China's SciBrunch Therapeutics ‌for rights to develop, manufacture and sell an experimental cancer treatment.

Read full article arrow
News Thumbnail
6:45 AM | Monday | Sep 28, 2026

Merck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015, an Investigational Oral KRAS G12D (ON) Inhibitor

Business Wire

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and SciBrunch Therapeutics Co., Ltd. (“SciBrunch”), today announced that they have entered into an exclusive global license agreement for SPR2015, an investigational preclinical oral KRAS G12D (ON) inhibitor.
“Evidence continues to accumulate for the therapeutic potential of targeting the KRAS pathway, a well-characterized factor in tumor cell growth,” said George Addona, senior vice president,.

Read full article arrow
News Thumbnail
12:20 PM | Friday | Sep 25, 2026

Merck's Remigromig Meets Main Goal in Diabetic Macular Edema Study

Zacks Investment Research

MRK's remigromig meets the primary goal in a DME study, showing non-inferiority to ranibizumab while further safety analyses continue.

Read full article arrow
News Thumbnail
6:45 AM | Friday | Sep 25, 2026

U.S. FDA Approves WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC)

Business Wire

RAHWAY, N.J. & NUTLEY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--FDA Approves WELIREG Plus LENVIMA for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC).

Read full article arrow
News Thumbnail
11:58 AM | Thursday | Sep 24, 2026

How a Roth IRA Can Keep Thousands More of Your DJIA Dividend Income Compounding

247 Wallst

Holding blue-chip Dow dividend payers in a taxable account quietly hands the IRS a cut of every reinvested dollar, year after year, and the compounding cost over two decades is far steeper than most investors expect.

Read full article arrow
News Thumbnail
7:56 AM | Thursday | Sep 24, 2026

Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

Fool - Investing News

Both face patent cliffs and pay generous dividends, but only one of them can tell you where its next wave of growth is coming from.

Read full article arrow
News Thumbnail